Dr Mariely Rivera-carrasquillo, PHD | |
Camino Los Ucares 458, Sabanera Del Rio, Gurabo, PR 00778-0077 | |
(787) 745-1196 | |
Not Available |
Full Name | Dr Mariely Rivera-carrasquillo |
---|---|
Gender | Female |
Speciality | Psychiatric Hospital |
Location | Camino Los Ucares 458, Gurabo, Puerto Rico |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1366735615 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TC0700X | Psychologist - Clinical | 3932 (Puerto Rico) | Secondary |
283Q00000X | Psychiatric Hospital | 3932 (Puerto Rico) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Mariely Rivera-carrasquillo, PHD # 458 Camino Los Ucares, Sabanera Del Rio, Gurabo, PR 00778 Ph: (787) 745-1196 | Dr Mariely Rivera-carrasquillo, PHD Camino Los Ucares 458, Sabanera Del Rio, Gurabo, PR 00778-0077 Ph: (787) 745-1196 |
News Archive
Just as our bodies physically slow down as we age, changes occur in the way that older bodies handle pharmaceuticals, and prescribing physicians need to be aware of those medications inappropriate for the elderly.
Around 20 percent of all humans are persistently colonized with Staphylococcus aureus bacteria, a leading cause of skin infections and one of the major sources of hospital-acquired infections, including the antibiotic-resistant strain MRSA.
The slowdown in global warming that was observed at the end of last century was reflected by a decrease in malaria transmission in the Ethiopian highlands, according to a study led by the Barcelona Institute for Global Health, an institution supported by "la Caixa" Foundation, and the University of Chicago.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
› Verified 5 days ago